Remdesivir Resistance in Transplant Recipients With Persistent Coronavirus Disease 2019

Clin Infect Dis. 2023 Jan 13;76(2):342-345. doi: 10.1093/cid/ciac769.

Abstract

New mutations conferring resistance to SARS-CoV-2 therapeutics have important clinical implications. We describe the first cases of an independently acquired V792I RNA-dependent RNA polymerase mutation developing in renal transplant recipients after remdesivir exposure. Our work underscores the need for augmented efforts to identify concerning mutations and address their clinical implications.

Keywords: antiviral resistance; immunocompromise; remdesivir; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); solid-organ transplant.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / therapeutic use
  • COVID-19 Drug Treatment
  • COVID-19*
  • Humans
  • SARS-CoV-2
  • Transplant Recipients

Substances

  • remdesivir
  • Antiviral Agents